(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.56%.
Cogent Biosciences's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast COGT's revenue for 2025 to be $2,631,095,807, with the lowest COGT revenue forecast at $1,278,083,855, and the highest COGT revenue forecast at $3,984,107,759. On average, 4 Wall Street analysts forecast COGT's revenue for 2026 to be $10,127,092,067, with the lowest COGT revenue forecast at $1,904,207,145, and the highest COGT revenue forecast at $16,133,655,565.
In 2027, COGT is forecast to generate $31,161,475,773 in revenue, with the lowest revenue forecast at $11,914,428,607 and the highest revenue forecast at $56,316,646,421.